Objectives: Non-small cell lung cancer (NSCLC) is a heterogeneous disease with unique combinations of somatic molecular alterations in individual patients, as well as significant differences in populations across the world with regard to mutation spectra and mutation frequencies. Here we aim to describe mutational patterns and linked clinical parameters in a population-based NSCLC cohort. Materials and methods: Using targeted resequencing the mutational status of 82 genes was evaluated in a consecutive Swedish surgical NSCLC cohort, consisting of 352 patient samples from either fresh frozen or formalin fixed paraffin embedded (FFPE) tissues. The panel covers all exons of the 82 genes and utilizes reduced target fragment length and two-strand capture making it compatible with degraded FFPE samples. Results: We obtained a uniform sequencing coverage and mutation load across the fresh frozen and FFPE samples by adaption of sequencing depth and bioinformatic pipeline, thereby avoiding a technical bias between these two sample types. At large, the mutation frequencies resembled the frequencies seen in other western populations, except for a high frequency of KRAS hotspot mutations (43%) in adenocarcinoma patients. Worse overall survival was observed for adenocarcinoma patients with a mutation in either TP53, STK11 or SMARCA4. In the adenocarcinoma KRAS-mutated group poor survival appeared to be linked to concomitant TP53 or STK11 mutations, and not to KRAS mutation as a single aberration. Similar results were seen in the analysis of publicly available data from the cBioPortal. In squamous cell carcinoma a worse prognosis could be observed for patients with MLL2 mutations, while CSMD3 mutations were linked to a better prognosis. Conclusion: Here we have evaluated the mutational status of a NSCLC cohort. We could not confirm any survival impact of isolated driver mutations. Instead, concurrent mutations in TP53 and STK11 were shown to confer poor survival in the KRAS-positive adenocarcinoma subgroup.
Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11 targeted successfully [11] [12] [13] [14] [15] . However, the majority of adenocarcinomas harbors an activating mutation in KRAS or lacks an identifiable oncogenic driver. Squamous cell carcinoma, although it is a heavily mutated malignancy, lacks common recurrent hotspot mutations in targetable driver genes [3] . Potential targets in squamous cell carcinoma that have been considered are mutated DDR2 and amplified FGFR1 [16, 17] . Other frequently mutated genes include MLL2, CDKN2A and PIK3CA [6] . For most patients with solid tumors only formalin fixed paraffin embedded (FFPE) samples are available in routine healthcare. This sampling bias is a problem for research on mutation spectra and associated biological and clinical impact in population-based clinical cohorts. Formalin fixation leads to fragmentation of the DNA and can induce artificial mutations during PCR amplification [18, 19] . Hence, in order to include all samples of a patient cohort for sequencing the techniques needs to be adapted to samples with poor DNA quality.
The first aim of this study was to evaluate the mutational status in a representative NSCLC cohort of patients treated with surgery at a single center. The goal was to avoid sample selection bias and to achieve population-based coverage by combined use of fresh frozen and FFPE samples in an optimized and robust targeted resequencing approach. The second aim was to assess the prognostic impact of mutations in individual genes as well as impact of co-mutation patterns, in relation to known clinical patient parameters.
Material and methods

Patient cohort
The patient material used for this study consisted of either fresh frozen or FFPE tissue from primary tumors from 352 NSCLC patients who underwent surgical resection at Uppsala University Hospital between 2006 and 2010 [20] . All fresh specimens were routinely processed for fresh frozen biobanking at the department of Pathology at Uppsala University Hospital, whereas the FFPE tissue blocks were obtained after fixation and further processing for routine diagnostics. In addition, non-neoplastic lung tissue samples from the specimens was included in the study for 35 of the patients. Lung pathologists performed re-evaluation of the original cases in accordance to the fourth edition of the WHO Classification of Lung Tumors [21] . Clinical parameters were obtained from the records of the population-based Uppsala-Örebro Regional Lung Cancer Registry -age at diagnosis, sex, smoking history, tumor stage, performance status (according to WHO) and overall survival (defined as time from surgery until date of death or last follow up). Information regarding adjuvant therapy was retrieved from patient records. The study was conducted according to the Swedish Biobank Legislation and Ethical Review Act (reference 2012/ 532, Ethical Review Board in Uppsala).
DNA preparation
DNA was extracted from either sections of fresh frozen tissue (200 samples) using the QIAamp DNA Mini Kit (Qiagen, Hamburg, Germany) or from 1 mm FFPE tissue cores (152 samples), using the QIAamp DNA FFPE Tissue Kit (Qiagen). DNA quantification was conducted with Qubit dsDNA BR assay kit (Life Technologies, Thermo Fisher Scientific Inc., Sunnyvale, CA, USA).
Target enrichment and sequencing
Using the Haloplex target enrichment system (Agilent Technologies, Santa Clara, CA, USA) target enrichment was performed with 200 ng input DNA. An assay targeting the coding exons of 82 genes was designed for this study. The design covers a total region of approximately 0.47Mb and uses 39,328 probes to capture the targeted genes. The design coverage and mean read depth for the individual genes is provided in Supplementary table S1. The panel design utilized reduced target fragment length and two-strand capture making it compatible with degraded FFPE samples, as previously described [22] . The enriched and amplified samples concentrations were determined using D1000 Screen Tapes (Agilent). Subsequently the samples were pooled in equimolar amounts and thereafter purified using the Agencourt AMPure XP system (Beckman Coulter, Indianapolis, IN, USA). The pooled samples were then sequenced on the Illumina HiSeq 2500 platform.
Data analysis
Alignment
CutAdapt version 1.8.0 was used to remove incorporated parts of the Illumina sequencing adaptors, which happens on target fragments shorter than the read length (150bp). Reads which had a read length of shorter than 1 bp after trimming were excluded from the analysis. The remaining trimmed reads were aligned to the reference genome (hg19, October 2010 assembly) using BWA version 0.7.12 (BWA settings; algorithm BWA-MEM, number of threads 3).
Variant detection
Detection of single-nucleotide variants was performed with SNPmania version 0.0.7. Only reads with a minimum base quality of 20 and alignment quality of 5 were considered during variant detection. The variants were then annotated using Annovar version 2015Mar22. To lower the number of possible causative variants a filtering against normal samples was done. Variants listed in the European 1000 genome database were excluded from further analysis, as well as all variants detected in thirty-five sequenced non-neoplastic lung samples from the study cohort. Only variants present on both the plus and minus strand, with at least a read depth of 30, predicted by Annovar to be non-synonymous and having a minimum variant allele frequency (VAF) of 5% were kept for further analysis, except for common hotspots in the genes EGFR, KRAS, BRAF, PIK3CA, ERBB2, MET and NRAS and variants located within the genes TP53 and STK11. For these genes variants with a VAF down to 1% were included.
Large indels
Large insertions and deletions (larger than 5 base pairs) were detected with Pindel version 0.2.5a8. The complete bam-file from Bwa was used for a non-targeted analysis with Pindel using the following parameters: max_range_index 2 and balance_cutoff 100. Indels detected on both the plus and minus strand with at least a read depth of 30 and a VAF of 5% were kept and a filtering was applied where all indels found in the non-neoplastic samples were excluded. The remaining indels were annotated using Annovar.
Statistics
Overall survival was analyzed using the Kaplan-Meier method and comparison of survival curves was done using the log-rank test. Multivariate Cox regression models were used to evaluate the relative risk of death of all causes, expressed as hazard ratios (HR) with 95% confidence intervals (CI). The multivariate models were adjusted for gender, age at surgery, pathological stage, smoking status, performance status and adjuvant therapy. Clinical characteristics for the patients at diagnosis are presented using standard descriptive statistics. Fisher´s exact test was used to analyze observed differences in frequencies, comparing the groups with mutated KRAS, EGFR, TP53, STK11, SMARCA4, APC, MLL2 and CSMD3 to cases with a wild-type phenotype in the respective genes. Multiple testing adjustments of significance levels were not performed. Statistical significance was set to p < 0.05. All analyses were performed using R version 3.2.0.
Results
Clinical samples and histopathologic data
In this study 352 NSCLC patients were included. Of these, 225 were classified as adenocarcinoma and 102 as squamous cell carcinomas. For thirty-five of the tumor samples a matched sample from adjacent, histologically non-neoplastic lung tissue was analyzed. A summary of clinical parameters is displayed in Table 1 .
Technical evaluation of sequencing strategy
The 82 genes selected for our study (Fig. 1A) have been shown to harbor genetic alterations that are believed to be relevant for the disease progression in NSCLC and present at a frequency of at least 1% in genome-wide studies of lung cancer cases [5, 6] . The gene panel covered 99.87% of the targeted coding regions and the sequencing yielded an average read depth of 4409 reads/base within the region of interest. In total, 2469 non-synonymous genomic alterations could be detected across the 352 lung cancer samples (Supplementary table S2) .
DNA from either fresh frozen (n = 200) or FFPE (n = 152) tumor samples was extracted for library preparation and targeted resequencing. A higher fraction of short sequencing reads (< 100bp) was obtained from FFPE samples, while longer reads (> 400bp) were almost completely absent (Fig.1B) . Still, by sequencing the FFPE samples at a greater depth and adaption of the bioinformatics pipeline for variant calling we obtained a uniform sequencing coverage (Supplementary figure S1) and mutational load (Fig. 1C) . The mean mutational load was 20.1 mutations/Mb in the fresh frozen samples and 18.8 mutations/Mb in the FFPE samples. Thus, technical bias was avoided with regard to the two sample types. Notably, the mean mutational load in our study is higher compared to other studies using whole exome sequencing. This is due to enrichment of commonly mutated genes included in the design of the targeted gene panel.
Mutation frequencies in lung tumors
The mutation frequencies in adenocarcinoma and squamous cell carcinoma for the 82 genes included in the study are listed in Supplementary table S3. The most frequently altered gene in both adenocarcinoma and squamous cell carcinoma was TP53, mutated in 47% and 85% respectively. Out of the total 245 TP53 variants 67% was considered pathogenic, 26% likely pathogenic and 7% variant of uncertain significance according to the TP53 database Seshat [23] . Either KEAP1 or NFE2L2 was mutated in 19% of adenocarcinoma cases and 23% of squamous cell carcinoma cases, in a mutually exclusive fashion [24] . Other frequently mutated genes in adenocarcinoma were KRAS (44%), EGFR (19%), STK11 (21%; 34% missense, 30% frameshift, 17% nonsense, 15% splice site mutation, 4% non-frameshift indel) and SMARCA4 (9%) (Fig. 2A) . Nine out of twenty adenocarcinoma patients with a SMARCA4 mutation also exhibited an activating KRAS mutation. An analysis of known hotspot mutations in KRAS and NRAS (codon 12, 13, 61, 146), EGFR (exon 18-21), ERBB2 (exon 20 insertions), MET (exon 14 skipping), BRAF (codon 466, 469, 581, 594, 596, 600, 601) and PIK3CA (exon 9 and 20) is summarized in Fig. 2B . Point mutations in hotspot regions in KRAS could be observed in 96 patients (43%). The majority of alterations occurred in codon 12 (n = 77, 80% of the KRAS mutated cases), most frequently p.G12C, p.G12 V and p.G12D. Eleven patients exhibited mutations in codon 13 (11%) whereas mutations in codon 61 and 146 where present in seven (7%) and one (1%) patients respectively. In EGFR, hotspot alterations were seen in 30 cases (13%), most frequently exon 19 deletions (n = 15, 50%) and p.L858R (n = 11, 37%). Exon 20 insertions in ERBB2 were seen in six patients (3%), predominantly p.E770_A771InsAYVM (n = 5). In other driver genes activating mutations were detected at low frequencies; BRAF (n = 5, 2%, p.V600E, p.K601E, p.G469 A, p.D594 G, p.G596R), NRAS (n = 1, < 1%, p.Q61 L), MET (n = 2, 1%, exon 14 skipping) and PIK3CA (n = 1, < 1%, p.E545 A). The occurrence of ALK rearrangements (n = 5, 2%) was assessed in a previous study [25] . In squamous cell carcinoma, frequently mutated genes were MLL2 (26%), PIK3CA (20%) and CDKN2 A (15%), whereas mutations in DDR2 was observed in 4% of patients (Fig. 2C) .
Prognosis linked to mutation status
Univariate analysis of overall survival was performed to evaluate the prognostic effect of genes with mutations occurring in ten or more cases in the adenocarcinoma or squamous cell carcinoma subgroups. Genes with a significant impact of mutation status on overall survival are shown in Fig. 3 , including KRAS and EGFR for reference. Descriptive statistics for these genes with regard to clinical baseline parameters are displayed in Supplementary table S4 (adenocarcinoma) and S5 (squamous cell carcinoma). In adenocarcinoma, no prognostic effect of mutation status in KRAS and EGFR could be demonstrated. Worse overall survival, or a trend for worse overall survival, were seen in patients with mutations in TP53 (p = 0.003), STK11 (p = 0.086) and SMARCA4 (p = 0.003), whereas patients with mutant APC had a better overall survival (p = 0.027) (Fig. 3) . In squamous cell carcinoma a worse overall survival was observed for patients with MLL2 mutations (p = 0.015) whereas patients with mutations in CSMD3 had a better prognosis (p = 0.034). An association to smoking was observed in adenocarcinoma patients with mutations in KRAS (p = 0.0002), TP53 (p = 0.018), STK11 (p = 0.021) and SMARCA4 (p = 0.05). Conversely, EGFR mutations were more commonly found in never-smokers (p = 1.53e-06) (Supplementary table S4) . In addition, female sex was associated with wild-type TP53 status (p = 0.043). No additional associations to clinical parameters reached significance, but this should be interpreted with caution due to small size of the subgroups in this analysis.
In multivariate analysis (Supplementary table S6) , following adjustment for gender, age, stage, smoking history and performance status, the differences in all-cause mortality remained significant between the mutated and wild-type group in adenocarcinomas for TP53 (HR = 1.47, 95% CI 1.02-2.13), STK11 (HR = 1.66, 95% CI 1.05-2.61) and SMARCA4 (HR = 2.1, 95% CI 1.22-3.61) and for CSMD3 (HR = 0.3, 95% CI 0.14-0.62) in squamous cell carcinoma. However, independent prognostic impact of APC mutations (HR = 0.5, 95% CI 0.18-1.37) in adenocarcinoma and MLL2 (HR = 1.81, 95% CI 0.96-3.41) in squamous cell carcinoma could not be confirmed. For completion, even though this study was not powered to assess the effect of adjuvant therapy in small genetic subgroups, and aware of risks with statistical "overfitting", a second multivariate Cox regression analysis (Supplementary table S7) was conducted with addition of this parameter. The difference in all-cause mortality dependent on mutation status remained significant for STK11 (HR = 1.8, 95% CI 1.11-2.93) and SMARCA4 (HR = 2.06, 95% CI 1.14-3.72) in adenocarcinoma. However, for TP53 (HR = 1.25, 95% CI 0.85-1,84) the survival impact of mutations as an independent variable did not remain significant. In squamous cell carcinoma, CSMD3 mutations (HR = 0.17, 95% CI 0.07-0.4) retained a significant independent positive prognostic impact.
Survival impact of co-occurring mutations in KRAS, TP53 and STK11
KRAS mutations in lung adenocarcinoma patients are frequently occurring together with mutations in TP53 and/or STK11 (Fig. 4A) . Of the 195 adenocarcinoma cases without an activating EGFR mutation, 81 were mutated in one of the three genes (KRAS n = 33, TP53 n = 45, STK11 n = 3), while 38 had a wild-type genotype in all three genes. Cooccurring mutations in two of the three genes were present in 73 patients (KRAS mut /TP53 mut n = 34, KRAS mut /STK11 mut n = 26, TP53 mut / STK11 mut n = 13), whereas three patients had mutations in all three genes. The best overall survival was observed in the wild-type and KRAS mut groups (Fig.4B) . However, there was no significant survival difference between these two groups (p = 0.91). Patients with an isolated TP53 mutation displayed a worse prognosis in comparison to both For cases with co-occurring mutations a significantly worse outcome could be seen for the KRAS mut /TP53 mut and KRAS mut /STK11 mut groups in comparison to the wild-type group (p = 0.038; p = 0.046 respectively). Inferior survival was also observed in comparison to the KRAS mut group lacking a co-mutation (p = 0.032; p = 0.04 respectively). To evaluate these findings in an independent cohort, mutation status and survival data from the MSK-IMPACT study [26] were retrieved from the cBioPortal [27, 28] (Fig. 4C) . A total of 576 lung adenocarcinoma patients (stage IeIV) were selected after removal of cases with an activating EGFR mutation. As in our cohort, the patients in the wild-type group and KRAS mut group exhibited a better prognosis, without a significant difference between each other (p = 0.24). On the other hand, patients with an isolated mutation in either TP53 or STK11 had a worse outcome in comparison to the wild-type group (p = 0.0016; p = 0.0023 respectively). (p = 0.0001).
Discussion
We have performed targeted resequencing of a consecutive population-based Swedish NSCLC cohort, assessing the mutation patterns in 82 genes commonly altered in NSCLC and evaluated the prognostic impact in different mutation subgroups. In order to include all samples in the cohort we used FFPE tissue for the patients lacking fresh frozen biobank material. The sequencing approach was adapted previously by members of our group to function well on degraded FFPE material by use of two-strand capture a reduced target fragment lengh [22] . In addition, the FFPE samples were sequenced at a greater depth and the bioinformatics pipeline was optimized to avoid technical biases between the two sample types.
At large, we observed mutation frequencies in our cohort comparable to other western populations, with an exception of a high frequency of activating KRAS mutations (43%) among lung 3 . Kaplan-Meier analysis of overall survival stratified by mutation status of the genes KRAS, EGFR, TP53, STK11, SMARCA4 and APC for adenocarcinoma patients and MLL2 and CSMD3 for squamous cell carcinoma patients; comparing mutated to wild-type. adenocarcinoma patients. The Cancer Genome Atlas and Clinical Lung Cancer Genome Project both report mutated KRAS in approximately 30% of lung adenocarcinomas [5, 29] . In more homogenous populations, a Dutch study describe KRAS mutations in 37% of the adenocarcinomas [30] , and in a previous Swedish study on NSCLC of mixed histologic subtypes the KRAS mutation rate in codon 12 and 13 was 29% [31] . As KRAS mutations are linked to smoking, we believe that the high rate of KRAS mutations in our cohort is explained by a high fraction of smokers (89%). Another explanation might be the high sensitivity of our assay, in combination with the ability to assess hotspot regions outside codon 12/13. Indeed, mutations in codons 61 and 146 accounted for 8% of the detected KRAS mutations.
The mutational status of a gene may have prognostic implications. In our study, after adjustment for confounding clinical parameters, we found that adenocarcinoma patients harboring mutations in TP53, STK11 or SMARCA4 had a worse overall survival. Some studies of NSCLC of mixed histologic subtypes do not show any prognostic impact of mutated TP53 [32, 33] . Other reports, including ours, show worse survival in lung adenocarcinoma patients with mutations in TP53 [34, 35] . However, separating the true prognostic and predictive impact of TP53, in relation to adjuvant therapy, has proven to be difficult [36] . Indeed, we could not confirm a significant prognostic impact of TP53 after adjustment for adjuvant therapy in multivariate analysis. The finding that mutations in STK11 conferred poor prognosis is supported by a trend for a worse survival in one study [37] , while another paper showed poor prognosis for patients with mutations in exon 1 and 2 of STK11 in comparison to mutations in exon 3-9 [38] . SMARCA4, a subunit in the SWI/SNF chromatin remodeling complex, is frequently mutated in lung adenocarcinoma. We observed a worse prognosis for patients harboring a SMARCA4 mutation. So far, to our knowledge, the mutational status of SMARCA4 and connection to prognosis have not been evaluated in NSCLC. Interestingly, there is data linking low gene expression of SMARCA4 to poor survival and results from in-vivo models showing good response to an OXPHOS inhibitor in SMARCA4 deficient xenografts [39, 40] . In squamous cell carcinoma, mutations in MLL2, a histone methyltransferase, was linked to worse overall survival, in concordance to previous reports [41] . Little is known about the function of CSMD3 (CUB and Sushi multiple domains 3), a predictive membrane protein with a role in adhesion. One report links mutations in this gene to better survival in patients with esophageal squamous cell carcinoma [42] . To our knowledge, the mutational status of CSMD3 and its impact on prognosis have not been evaluated in NSCLC before. Notably, in our study it represents the gene with the most profound independent impact on prognosis (HR 0.17 and 0.3, with and without adjustment for adjuvant therapy in multivariate analysis). We could not detect an impact on overall survival for any other gene with recurrent mutations in our gene panel. A limitation of this exploratory study is that adjustment for multiple testing was not performed, creating a risk for false positive results. We here interpret the results based on known functional roles of genes and mutations in addition to supportive evidence from other studies. However, further studies are needed to confirm the described clinical impact of the respective mutations.
A large fraction of lung adenocarcinomas in western populations harbor an activating mutation in KRAS [43] . These KRAS mutations are frequently accompanied by mutations in the tumor suppressor genes TP53 and STK11. We observed that patients with an isolated KRAS mutation had an overall survival similar to the wild-type group, whereas patients with co-occurring mutations in either TP53 or STK11 had a worse overall survival in comparison to the wild-type group and Fig. 4. (A) Venn-diagram showing the overlap of mutations in the genes KRAS, TP53 and STK11 for the 195 EGFR negative adenocarcinomas included in this study. (B) Kaplan-Meier analysis of overall survival stratified by the mutation status in the three genes KRAS, TP53 and STK11 for the Uppsala NSCLC cohort. (C) Kaplan-Meier analysis of overall survival of 576 adenocarcinomas (stage I-IV) from the MSK-IMPACT study, stratified by the mutation status in the three genes KRAS, TP53 and STK11. The data from the MSK-IMPACT study were retrieved from the cBioportal and only lung adenocarcinoma patients with available survival data and complete mutation data in the genes KRAS, TP53, STK11 and EGFR were included. Patients with an activating EGFR mutation were excluded from the analysis.
the KRAS only group. Our results were further supported by data from the MSK-IMPACT study. Other studies looking at the prognostic impact of co-occurring mutations in TP53 or STK11 together with KRAS have been inconclusive [37, 44] . Gene expression analysis in lung adenocarcinoma has shown that TP53 mutations enhance signatures related to cell proliferation in contrast to STK11 mutations that boost expression of genes induced by KRAS mutations and suppress signatures related to immune function [45] . Thus, from a functional perspective the negative prognostic impact of co-mutations in TP53 or STK11 might be explained by proliferative drive and poor immune function respectively in the two subgroups. At the same time, from the perspective of immune therapy, TP53 and STK11 appear to have completely opposite impact. Tumors with TP53 mutations, especially with co-occurring KRAS mutations, generally demonstrate dense infiltration of CD8+ T-cells in combination with high expression of PD-L1, and tend to respond well to checkpoint inhibitor therapy [46, 47] . Conversely STK11 mutations were linked to decreased immune cell infiltration, low PD-L1 expression, and poor response to PD-L1 inhibition. Indeed, recent studies on larger patient cohorts confirm STK11 mutations as a prominent predictor of resistance to checkpoint inhibitor therapy, partly independent of PD-L1 expression and tumor mutation burden [48, 49] . In view of the described complex prognostic and predictive effects we believe that it might be relevant to include analysis of TP53 and STK11 in molecular testing algorithms. Interestingly, these genes are covered in most established small targeted NGS panels routinely used in reflex testing algorithms for driver mutations in NSCLC.
Conclusion
We have analyzed mutations in 82 genes associated with lung cancer development in a Swedish NSCLC cohort. Bias due to sample selection, FFPE versus fresh-frozen tissue, was avoided by technical adaptation of the targeted sequencing method. At large the mutation spectra resemble findings in other western lung cancer populations, with an exception of a high KRAS mutation rate in adenocarcinoma. A poor prognosis could be linked to mutations in TP53, STK11 or SMARCA4 in adenocarcinoma and MLL2 mutations in squamous cell carcinoma, while mutations in CSMD3 were linked to a better prognosis in squamous cell carcinoma. Interestingly, we show that TP53 and STK11 mutations confer poor survival in the KRAS-positive subgroup, but not KRAS mutations themselves as an isolated aberration, suggesting that co-mutations beside commonly tested driver mutations in the MAP-kinase pathway are important determinants of aggressive behavior after surgery of lung cancer, as well as strong predictors of immune therapy response.
